Latest news

• AZ/Oxford University’s COVID-19 vaccine to be evaluated in children and young adults

  The new phase 2 trial will enrol 300 participants, with up to 240 of these volunteers receiving the vaccine – known as ChAdOx1 nCoV-19 or AZD1222 – while the remainder will be

• AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly

  German media reports suggested vaccine is less than 10% effective in the elderly

• Pfizer/BioNTech's COVID-19 vaccine found to be effective against UK virus variant

  British pharma company AstraZeneca also told Reuters that its COVID-19 vaccine, AZD1222, should be effective against the new UK variant.

• Trial combining British and Russian COVID-19 vaccines could begin in February

  On 11 December 2020, AZ announced "a clinical trial programme to assess the safety and immunogenicity of a combination of AZD1222, developed by AstraZeneca and Oxford University, and Sputnik V, developed ... The interim analysis for efficacy of the

• Pfizer/BioNTech vaccine shown to be effective against new COVID-19 variants

  British pharma company AstraZeneca also told Reuters that its COVID-19 vaccine, AZD1222, should be effective against the new UK variant.